61101-89-1

Upstream product

• 108-73-6 3,5-dihydroxyphenol 
• 5106-98-9 4-chlorosalicylic acid 
• 100334-99-4 2,4-Dichloro-benzoic acid 4-(2,4-dichloro-benzoyl)-3,5-dihydroxy-phenyl ester 
• 89-75-8 2,4-dichlorobenzoyl chloride 
• 10586-12-6 phloroglucinol tris(trimethylsilyl) ether 

Relevant academic research and scientific papers

Synthesis and antitumor, antityrosinase, and antioxidant activities of xanthone

Ten substituted 1,3-dihydroxyxanthones were synthesized in one step. The yields ranged from 40 to 76%. Compounds 8–10 were first reported. Next, the compounds’ in vitro anti-proliferative activities against nine human cancer cell lines, antityrosinase, and antioxidant activities were evaluated. Compounds 1, 4, 6–7, and 9–10 exhibited enhanced cytotoxicity against certain cancer cells. Compounds 2, 8, 9, and 10 inhibited tyrosinase activity to a certain extent. In addition, compound 4 exhibited the best antioxidant activity, which was consistent with theoretical calculations. These results demonstrated that compounds 1–2, 4, and 6–10 were promising leads for further investigation.

Xanthones compounds and its antidepressant

The invention discloses xanthone compounds and their use in depression resistance. The xanthone compounds are compounds shown in the structural formula (I) or their pharmaceutically acceptable salts. An experiment proves that the xanthone compounds have good depression-resistant activity and a part of the xanthone compounds have depression-resistant activity superior to that of venlafaxine. Therefore, the xanthone compounds and their pharmaceutically acceptable salts can be used for preparation of depression-resistant drugs.